Imatinib mesylate (IM) treatment markedly reduces the burden of leukemia cells in chronic myelogenous leukemia (CML) patients. However, patients remain at risk for relapse on discontinuing treatment. We have previously shown that residual BCR-ABL+ progenitors can be detected in CML patients within the first two years of IM treatment. However reduced rates of relapse and continued decline of BCR-ABL levels with prolonged IM treatment, together with the ability of selected patients to maintain remission after discontinuing IM treatment, led us to investigate whether prolonged IM exposure resulted in reduction or elimination of BCR-ABL+ stem cells. We evaluated BCR-ABL expression in CD34+CD38+ (38+) committed progenitors and CD34+CD38-(38-) stem/primitive progenitor cells in samples from CML patients on IM treatment for at least 4 years with cytogenetic and molecular response. We observed that high levels of BCR-ABL expression were maintained over time in the 38-stem cell fraction. The absolute frequency of BCR-ABL+ cells as determined by limiting dilution analysis was consistently higher in 38-compared with 38+ cells. Transplantation into NOD/SCID-IL2Rγ-chain knockout mice demonstrated that BCR-ABL+ cells had long-term in vivo repopulating capacity.
Introduction:
Chronic myeloid leukaemia (CML) results from hematopoietic stem cell transformation by the BCR/ABL gene. 1 Treatment with the BCR-ABL kinase inhibitor Imatinib mesylate (IM, Novartis) results in sustained clinical remissions in CML patients with major reduction in BCR-ABL transcript levels on Q-PCR analysis. 2 However the majority of patients achieving remission with IM continue to have molecular evidence of persistent disease. 3 Mathematical modeling of the kinetics of reduction of BCR-ABL levels in IM-treated CML patients suggest that IM has increased activity against progenitors and mature cells and limited activity against stem cells. 4, 5 Laboratory studies confirm heterogeneity of response of different cell types to IM, with quiescent CML stem cells being the most resistant to IM-induced apoptosis. 6, 7 We and others have shown that CML stem cells are also insensitive to the second-generation ABL tyrosine kinase inhibitors (TKI) nilotinib and dasatinib. [8] [9] [10] [11] [12] There is a high likelihood of leukemia relapse on discontinuation of treatment, and it is currently recommended that patients receive IM indefinitely to prevent relapse, with associated risk of side-effects and considerable expense.
We have previously shown that residual BCR-ABL expressing CD34+ cells, CFC and LTCIC can be detected in the bone marrow (BM) of patients in remission with IM treatment. 3 These earlier studies were carried out in patients who had been treated with IM for less than 2 years.
Other groups have reported that BCR-ABL expressing CML progenitors were eradicated within a year of starting IM treatment whereas BCR-ABL-positivity continued to be seen in the stem cell compartment, although at reduced levels. 13 On the other hand BCR-ABL levels continue to slowly decline over time in CML patients with prolonged IM treatment. 14 In addition the rate of disease relapse in patients receiving IM treatment decreases with ongoing treatment. 15 Finally a proportion of IM-treated patients that achieve undetectable levels of BCR-ABL on Q-PCR analysis maintain sustained remissions after discontinuation of IM treatment [16] [17] [18] . These observations raise the possibility that prolonged IM treatment may be associated with reduction For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From or elimination of CML stem cells. The ability to directly measure residual leukemia stem cells in CML patients would considerably assist assessment of the effects of treatments against this population.
In the current study we evaluated residual leukemia stem cell levels in patients who had been treated with IM for at least 4 years and who were followed at our center. Our results directly demonstrate the persistence of BCR-ABL+ stem cells in the BM of CML patients in prolonged remission on IM treatment.
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Material and Method:
Patients and samples: CML patients followed at COH (n=20) treated with IM for 4 or more years from whom cryopreserved bone marrow (BM) samples were available were studied.
Patients were in complete cytogenetic response (CCR) and 19 patients were reported to be in complete molecular response by the clinical laboratory at time of study. Of these 12 patients were consistently negative on PCR evaluation. The Q-PCR assay used by the clinical laboratory detects BCR-ABL transcripts corresponding to a BCR-ABL: BCR ratio of 0.1%, or a 3-log reduction on the International scale, but does not detect lower levels of BCR-ABL transcripts.
Mononuclear cells were isolated using Ficoll-Hypaque density gradient separation. Cells were cryopreserved in DMSO-containing medium in liquid nitrogen tanks (vapor phase). Frozen cells were thawed and incubated in IMDM supplemented with 20% FBS and DNAse I (Sigma) for 3 hours at 37°C prior to further processing. CD34+ cells were isolated from BM mononuclear cells (MNC) by immunomagnetic column separation (Miltenyi Biotec Inc. Auburn, CA, and Stem Cell Technologies, Vancouver, BC, Canada). Column-selected CD34+ cells were labeled with anti-CD34-APC (clone 8G12) and anti-CD38-PE (clone HB7) antibodies (Becton Dickinson, San Jose, CA), and CD34+CD38+ (38+) committed progenitors and CD34+CD38-(38-) stem or primitive progenitor cells were isolated by flow cytometry sorting.
Real-time quantitative RT-PCR analysis.
Total RNA was extracted from MNC; CD34+CD38+ cells and CD34+CD38-cells using RNeasy mini or micro kits (Qiagen, Valencia, CA). First strand cDNA was synthesized using the Superscript TM III first strand kit (Life Technologies Corporation, Carlsbad, CA). Reactions were performed in a total volume of 20 µl. Quantitative PCR analysis for detection of BCR/ABL and BCR transcripts was performed using a TaqMan universal PCR master mix kit and the ABI Prism 7900 sequence detector (Applied Biosystems, Foster City, CA). Primer and probe sequences for B3A2 and BCR were as previously described 19 . Quantitation standards for Q-PCR were prepared by PCR amplification of B3A2, PCR analysis for BCR/ABL was performed as described above. 
Results
CML patients who had been treated with IM for at least four years and had achieved complete cytogenetic response (CCR) and molecular response (undetectable BCR-ABL on Q-PCR analysis in the clinical laboratory) were studied; with the exception of one patient whose samples were used in murine engraftment studies. The clinical characteristics of these patients are listed in Table1. All patients were in chronic phase at start of IM treatment. The median age of patients was 54 years (range 25 to 68 years). Eight patients (40%) had received IFN or IFN+ Ara-C prior to starting IM. The median time to starting IM was 1.5 months (range 0 to 31 months) and from starting IM to CCR was 6 months (range 3 to 34 months). Twelve patients were consistently in complete molecular response whereas 7 patients were intermittently in molecular response. The Q-PCR assay used in our laboratory was more sensitive than the clinical assay and detected BCR-ABL expression in MNC samples from all patients. Our results indicated that 7 of 13 patients had achieved CMR, 3 patients had achieved MMR, and 3 patients less than MMR, based on the International Scale. Higher level of BCR-ABL were maintained in CD34+CD38cells, compared with levels in MNC and CD34+CD38+ cells, over 5 years of IM treatment.
Differences between MNC and CD38-cells were significant in years 1 and 3 (p<0.01 and p<0.001 respectively), and trended towards significance in years 4 and 5 (p=0.09). Differences between CD38+ and CD38-cells were significant at year 3 (p<0.05), and trended towards significance in years 4 and 5 (p=0.07 and 0.1). We did not observe significant differences in BCR-ABL mRNA levels in CD38+ and CD38-cells between patient groups with different levels of response. These results indicate that BCR-ABL+ stem or primitive progenitor cells can persist in the BM of patients receiving prolonged IM treatment.
BCR-ABL levels measured using Q-PCR analysis represent the average expression level for the cell population analyzed. However BCR-ABL expression may vary between individual cells and average BCR-ABL expression levels could be disproportionately affected by a minority of cells with high expression levels. Therefore BCR-ABL levels measured by Q-PCR may not necessarily represent the frequency of BCR-ABL positive cells in the population analyzed.
Limiting dilution analyses are a well established approach to estimating frequencies of specific cells in a mixed population. 20, 21 We adapted the limiting dilution assay format to estimate the frequency of BCR-ABL+ cells in CD34+38+ and CD34+38-populations. Selected cells were distributed into 96-well plates at four different concentrations per well with multiple replicates per concentration. Nested PCR was performed and wells scored as positive or negative for BCR-ABL. The frequency of BCR-ABL+ cells in different subpopulations was calculated using Poisson statistics (Figure 3) . Since frequency is calculated on the basis of the proportion of negative wells rather than positive wells, it is not affected by the level of BCR-ABL expression per cells. The estimated frequencies of BCR-ABL+ cells in the CD34+CD38+ and CD34+CD38-subpopulations in serial samples (n=14 samples, 28 assays) from 6 patients is shown in Figure   3 and Table 2 . These results confirm that the limiting dilution analysis is a robust approach to measure the frequency of BCR-ABL expressing cells and clearly demonstrate that there is increased frequency of BCR-ABL+ cells within the CD34+CD38-population (0.59±0.1%) Table 2) . These results are consistent with the frequency of BCR-ABL+ cells within the CD34+CD38-fraction observed using limiting dilution analysis (0.59%), which is at the limit of detection of the FISH assay.
To determine whether residual BCR-ABL+ cells in IM-treated patients retain functional long-term engrafting capacity, CD34+ cells from 6 patients were transplanted into immunodeficient NSG mice. Patients had been on IM treatment from 4 to 9 years (Table S1). Cells from each patient were injected into 3-4 mice (total of 20 mice). The number of cells and mice injected are shown in Table S1 . Mice were evaluated for engraftment with human cells and presence of BCR-ABL expressing cells in BM, spleen and PB at 11-12 weeks after transplantation (Figure 4A) . The level of engraftment of human CD45+ cells was consistent in mice receiving samples from a single patient, and ranged from 25 to 50% for individual patients (Figure 4B) .
Immunophenotypic characterization of engrafted human CD45+ cells demonstrated multilineage
engraftment of myeloid and lymphoid cells (Figure 4C) . BCR-ABL expression was detected by Q-PCR in human cells engrafted in the BM of mice receiving transplants from each patient For personal use only. on September 14, 2017. by guest www.bloodjournal.org From (Figure 4D) . These results indicate that BCR-ABL+ cells with functional in vivo repopulating capacity are retained in patients in remission on IM treatment.
Discussion
In this study we show that BCR-ABL+ stem and primitive progenitor cells are retained in CML patients in remission on prolonged IM treatment. We observed an increased frequency of BCR-ABL+ cells in the CD34+CD38-stem/primitive progenitor population compared to CD34+CD38+ committed progenitors, with no decrease in BCR-ABL levels within the CD34+CD38-population from one to five years post-treatment. Residual BCR-ABL+ cells retained functional long-term repopulating capacity as assessed by their ability to generate BCR-ABL+ cells after transplantation to immunodeficient mice. These results are of considerable importance since they directly demonstrate the selective retention of leukemia stem cells in the BM of IM-treated CML patients. Moreover they show that residual leukemia stem cells can be accurately enumerated and evaluated for functional capacity. These results may have important implications not only for the assessment of the effects of different TKIs against leukemia stem cells, but also for studies of discontinuation of TKI treatment, and for evaluation of treatments directed against leukemia stem cells.
Discontinuation of IM treatment is usually associated with disease relapse, and it is currently recommended that patients continue to receive IM treatment indefinitely in order to maintain remission. 18, 22 However prolonged IM treatment may be associated with risks of long-term complications, reduced compliance, drug resistance and considerable ongoing costs. Ongoing clinical trials of IM discontinuation indicate that approximately 40% of a select group of patients that achieve sustained BCR-ABL negative state on Q-PCR analysis do not relapse after discontinuation of IM. [16] [17] [18] However there is evidence that the original leukemic clone persists in CML patients who are in CMR after allogeneic transplantation or IM treatment. 23 Even patients who maintain sustained CMR after IM discontinuation show evidence of persistent BCR-ABL positive cells when evaluated using more sensitive assays such as DNA PCR. 17 These results indicate that BCR-ABL+ cells are retained in virtually all CML patients treated with IM if For personal use only. on September 14, 2017. by guest www.bloodjournal.org From sensitive-enough tests are used, and that CMR needs to be defined on the basis of the sensitivity of the assay used. There is an evolving consensus to report BCR-ABL levels based on assay sensitivity, such as CMR 4.0 or CMR 4.5 (complete molecular response 4 logs reduction, molecular response 4.5 logs reduction). 24 Information regarding the frequency of residual leukemia stem cells could potentially impact treatment of CML patients by providing a measurement of the depth of response. Alternatively the capacity of residual stem cells to proliferate and regenerate leukemia cells may be more important in determining risk of disease regeneration and relapse. Although the patients evaluated in the current study may differ from those enrolled in IM discontinuation trials, it will be For personal use only. on September 14, 2017. by guest www.bloodjournal.org From of interest to determine whether the assays described here can provide a better predictor of recurrence on discontinuing treatment compared to analysis of bulk mononuclear cells. These assays may also provide a surrogate endpoint for evaluating other treatments designed to reduce leukemia stem cells and enhance the proportion of patients in whom treatment can be discontinued without disease recurrence. It will be of great interest to perform assessment of residual stem cells as described in the current study in a cohort of patients who have discontinued IM treatment, to determine whether the frequency of leukemia stem cells can predict for risk of recurrence after IM discontinuation.
The number of patients who maintain molecular remission after stopping IM treatment represents only a small fraction of patients initially started on treatment with IM. There is considerable interest in developing new treatment approaches to improve the proportion of patients in whom IM treatment can be discontinued without disease relapse. Several strategies to target residual leukemia stem cells are in various stages of clinical development. [25] [26] [27] However these approaches are limited by the lack of methods for evaluating the effects of treatments on CML stem cells. Enumeration of CML stem cells and assessment of leukemia-initiating capacity using the methods described here could be of great value for evaluating the ability of different treatments to target, reduce or eliminate CML stem cells. Obstacles to the clinical application of these methodologies include their relatively cumbersome nature and the limited number of cells available for analysis from patient samples that could limit the sensitivity or result in failure of the assay. Modifications that can be used to enhance sensitivity of the assays include the use of improved methodologies for RNA extraction from small samples and addition of a preamplification step to enhance the robustness and reliability of the procedure. The use of newer technologies employing microfluidic devices and sensitive molecular detection techniques may be particularly helpful for efficient, quantitative evaluation of small samples. 28 For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
The current studies also have implications to other leukemias and solid tumors that arise from malignant stem cell populations. Recently rare leukemia stem cells resistant to therapeutic targeting were detected in patients with del(5q) myelodysplastic syndrome at the time of complete clinic cytogenetic remission. 29 Improved approaches to directly assess and enumerate residual cancer stem cells will be of increasing importance to determine the effect of available treatments, and guide the development and application of new strategies to target these important populations. The current studies demonstrate the feasibility of such approaches and provide a framework for development of strategies to enumerate residual cancer stem cells and study their functional capacity. Table 2 
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